Genetic testing for cancer risk, known as Oncogenetics, is a highly standardized field within the Italian healthcare system. The primary focus is on identifying individuals with hereditary mutations in genes such as BRCA1 and BRCA2, which significantly increase the risk of breast and ovarian cancer.

National guidelines require that patients undergo professional genetic counseling both before and after testing. This ensures that individuals understand the potential implications for themselves and their family members. In 2026, Italian clinics use "Multi-Gene Panels" that look at a broad range of high-risk genes simultaneously (including CHEK2, PALB2, and ATM). This comprehensive approach allows for "Precision Prevention," where high-risk individuals can choose more frequent screening (like annual MRIs) or preventive surgeries, drastically reducing the mortality rate from hereditary cancers across the Italian population.